Matthew A Powell, MD
Baik CS et al. Immuno-oncology clinical trial design: Limitations, challenges, and opportunities. Clin Cancer Res 2017;23(17):4992-5002. Abstract
Castellano T et al. An overview of immune checkpoint inhibitors in gynecologic cancers. Clin Ther 2018;40(3):372-88. Abstract
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39(1):1-10. Abstract
Disis ML et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: Safety and clinical activity. Proc ASCO 2016;Abstract 5533.
Fleming GF et al. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). Proc ASCO 2017;Abstract 5585.
Frenel JS et al. Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase 1b KEYNOTE-028 study. Proc ASCO 2016;Abstract 5515.
Hamanishi J et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015;33(34):4015-22. Abstract
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144(5):646-74. Abstract
Hollebecque A et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. Proc ASCO 2017;Abstract 5504.
Lheureux S et al. A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. Proc ASCO 2015;Abstract 3061.
Matulonis UA et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. Proc ASCO 2018;Abstract 5511.
Ott PA et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. J Clin Oncol 2017;35(22):2535-41. Abstract
Oaknin A et al. Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer. Proc ESMO 2018;Abstract 935PD.
Tang J et al. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 2018;29(1):84-91. Abstract
Varga A et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecol Oncol 2019;152(2):243-50. Abstract
Zehir A et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23(6):703-13. Abstract
Zhang L et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13. Abstract
Michael J Birrer, MD, PhD
Moore KN et al. IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts). Proc ASCO 2016;Abstract 5567.
Naumann RW et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 2010;28(Supp 18):LBA5012b. Abstract
David M O’Malley, MD
Breij EC et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014;74(4):1214-26. Abstract
Cocco E et al. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer 2011;11:263. Abstract
Concin N et al. A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort. Proc ESMO 2018;Abstract 963P.
de Goeij BE et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther 2015;14(5):1130-40. Abstract
Förster Y et al. Tissue factor and tumor: Clinical and laboratory aspects. Clin Chim Acta 2006;364(1-2):12-21. Abstract
Shannon N Westin, MD, MPH
Bouzin C et al. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: Identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol 2007;178(3):1505-11. Abstract
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39(1):1-10. Abstract
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13(4):227-42. Abstract
Coukos G et al. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 2005;92(7):1182-7. Abstract
Galluzzi L et al. The secret ally: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012;11(3):215-33. Abstract
Gavalas NG et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012;107(11):1869-75. Abstract
Hannani D et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 2011;17(5):351-8. Abstract
Jiao S et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23(14):3711-20. Abstract
Konstantinopoulos PA et al. TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC) — Results from ROC cohort. Proc ASCO 2018;Abstract 106.
Makker V et al. Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results. Proc ASCO 2018;Abstract 5596.
Makker V et al. A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. Proc ASCO 2017;Abstract 5598.
Rotte A et al. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 2018;29(1):71-83. Abstract
Shrimali RK et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70(15):6171-80. Abstract
Terme M et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013;73(2):539-49. Abstract
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12(4):237-51. Abstract
Zitvogel L et al. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8(3):151-60. Abstract